Lamellar macular hole after intravitreal ocriplasmin injection

Ross Bronson Chod; Clifford Goodrich; Sandeep Saxena; Levent Akduman

doi:10.1136/bcr-2014-207810

Lamellar macular hole after intravitreal ocriplasmin injection

Ross Bronson Chod, Clifford Goodrich, Sandeep Saxena, Levent Akduman

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Intravitreal ocriplasmin was recently approved by the Food and Drug Administration to achieve medical vitreolysis in the setting of vitreomacular adhesion (VMA). We report a case of a 76-year-old woman who developed a lamellar macular hole following treatment with intravitreal ocriplasmin injection for VMA. A pathophysiological mechanism to explain this previously unreported complication of ocriplasmin injection is proposed.

Original language	English (US)
Article number	207810
Journal	BMJ Case Reports
Volume	2015
DOIs	https://doi.org/10.1136/bcr-2014-207810
State	Published - Jan 9 2015
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1136/bcr-2014-207810

Cite this

@article{6a24a1a0bb3545bd852a39eb0806cb1f,

title = "Lamellar macular hole after intravitreal ocriplasmin injection",

abstract = "Intravitreal ocriplasmin was recently approved by the Food and Drug Administration to achieve medical vitreolysis in the setting of vitreomacular adhesion (VMA). We report a case of a 76-year-old woman who developed a lamellar macular hole following treatment with intravitreal ocriplasmin injection for VMA. A pathophysiological mechanism to explain this previously unreported complication of ocriplasmin injection is proposed.",

author = "Chod, {Ross Bronson} and Clifford Goodrich and Sandeep Saxena and Levent Akduman",

year = "2015",

month = jan,

day = "9",

doi = "10.1136/bcr-2014-207810",

language = "English (US)",

volume = "2015",

journal = "BMJ Case Reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Lamellar macular hole after intravitreal ocriplasmin injection

AU - Chod, Ross Bronson

AU - Goodrich, Clifford

AU - Saxena, Sandeep

AU - Akduman, Levent

PY - 2015/1/9

Y1 - 2015/1/9

N2 - Intravitreal ocriplasmin was recently approved by the Food and Drug Administration to achieve medical vitreolysis in the setting of vitreomacular adhesion (VMA). We report a case of a 76-year-old woman who developed a lamellar macular hole following treatment with intravitreal ocriplasmin injection for VMA. A pathophysiological mechanism to explain this previously unreported complication of ocriplasmin injection is proposed.

AB - Intravitreal ocriplasmin was recently approved by the Food and Drug Administration to achieve medical vitreolysis in the setting of vitreomacular adhesion (VMA). We report a case of a 76-year-old woman who developed a lamellar macular hole following treatment with intravitreal ocriplasmin injection for VMA. A pathophysiological mechanism to explain this previously unreported complication of ocriplasmin injection is proposed.

UR - http://www.scopus.com/inward/record.url?scp=84921685214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921685214&partnerID=8YFLogxK

U2 - 10.1136/bcr-2014-207810

DO - 10.1136/bcr-2014-207810

M3 - Article

C2 - 25576512

AN - SCOPUS:84921685214

SN - 1757-790X

VL - 2015

JO - BMJ Case Reports

JF - BMJ Case Reports

M1 - 207810

ER -

Lamellar macular hole after intravitreal ocriplasmin injection

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this